Control of foodstuffs and medicines USA (FDA) approved the production of a new generic drug Vitrakvi against cancer, was developed by company Loxo Oncology, in collaboration with the company Bayer. A feature of the drug is that it is designed to combat the mutations in tumours at the genetic level. The technique can be used to treat any type of cancer — all that matters is the type of genetic distortion, not the location of the cancer. This publication reports Business Insider.
The medication is very expensive. A year’s supply of Vitrakvi 393 will cost thousands of dollars. In a statement, Bayer said that every year, 2500-3000 people diagnosed genetic mutations leading to the development of cancer. It is also reported that for children the drug will be produced in liquid form, and the annual volume of this case will be reduced to 132 000 $ per year. Bayer also reports that is going to offer financial assistance to those patients who are not able to pay the full cost of the medication. In this case, their price will significantly drop the cost of a monthly stock Vitrakvi will be $ 20, which is absolutely feasible for most patients.
“Today’s approval is another important step in the fight various types of cancer based on their tumor genetics, and not just on the basis of their local origin in the body”, reported on the website of the Directorate for control of food and medicines of the USA.
In 2017, Loxo Oncology has signed with pharmaceutical giant Bayer agreement of $ 1.5 billion for the development and introduction on the commercial market of two drugs Loxo, including Vitrakvi. During the tests this drug called paratrechina (larotrectinib LOXO-101).
The use of funds aimed at specific genetic mutations, represents a new approach in cancer treatment. Most pharmaceutical companies develop drugs aimed at the treatment of a specific type of cancer, e.g. lung cancer or melanoma. In this case, it is necessary each time to obtain the approval of the regulatory bodies to check the impact of these drugs on other cancers.
The deciphering of the genetic pattern of tumors is often used in modern medicine. However, this approach has attracted much attention only in 2013, when scientists found that endometrial cancer has a similar genetic picture of ovarian cancer and breast.
In may 2017, the FDA approved the first drug aimed at the treatment of genetic mutations that paved the way for developing similar tools by other manufacturers, including Loxo. New drug Loxo Oncology affects a certain type of mutation — TRK-fused gene. It leads to the development of various types of cancer: sarcoma, thyroid cancer, small cell lung cancer and other types.
Conducted drug tests on humans showed positive results. At the last meeting of the European society of medical Oncology Loxo Oncology said that among the 109 patients treated with this drug in studies, 81 per cent observed generally positive dynamics in the treatment – the size of tumours decreased. While in 17 percent of patients had a positive response – the cancer had completely retreated from their body.
To discuss the news in our Telegram chat.